Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novo Nordisk
Novo Nordisk
Novo’s Wegovy Launched in China at a Fraction of US Price
BioSpace
Mon, 11/18/24 - 11:28 am
Novo Nordisk
Wegovy
Cina
weight loss
GLP-1 agonists
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Fri, 11/15/24 - 11:27 am
Omada Health
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Zepbound
Mounjaro
Wegovy
Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO
Beckers Hospital Review
Thu, 11/7/24 - 11:14 am
Novo Nordisk
Ozempic
semaglutide
compounded drugs
FDA adds aspiration warning to Ozempic, Mounjaro and other GLP-1 labels
Beckers Hospital Review
Wed, 11/6/24 - 08:01 pm
FDA
warnings
aspiration
Ozempic
Wegovy
Saxenda
Mounjaro
Novo Nordisk
Eli Lilly
Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail
Fierce Biotech
Wed, 11/6/24 - 08:00 pm
Novo Nordisk
kidney disease
clinical trials
ocedurenon
Novo Nordisk Q3 earnings: Wegovy sales soar 79% year-over-year
Yahoo Finance
Wed, 11/6/24 - 11:44 am
Novo Nordisk
Wegovy
earnings
States slow to cover GLP-1s for weight loss
Axios
Wed, 11/6/24 - 11:37 am
Medicaid
GLP-1 agonists
Novo Nordisk
Eli Lilly
Wegovy
Zepbound
Wegovy reduces all-cause admissions: 3 study findings
Beckers Hospital Review
Mon, 11/4/24 - 11:19 am
Novo Nordisk
Wegovy
hospital admissions
clinical trials
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Fierce Biotech
Mon, 11/4/24 - 11:13 am
Novo Nordisk
Ascendis Pharma
biobucks
drug development
Novo, with new results, to seek approval for obesity drug in MASH
BioPharma Dive
Fri, 11/1/24 - 11:25 am
Novo Nordisk
semaglutide
MASH
Novo takes big step toward ending Ozempic, Wegovy shortages
BioPharma Dive
Wed, 10/30/24 - 08:48 pm
Novo Nordisk
drug shortages
obesity
Ozempic
Wegovy
Backlash builds against Novo’s Catalent takeover
Pharma Voice
Wed, 10/30/24 - 11:40 am
Novo Holdings
Novo Nordisk
Catalent
M&A
Roche
Weight-loss drugs didn't curb health costs within two years
Reuters
Thu, 10/24/24 - 11:11 am
Novo Nordisk
Eli Lilly
Wegovy
Zepbound
obesity
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Reuters
Thu, 10/24/24 - 09:53 am
Eli Lilly
Mounjaro
Novo Nordisk
Denmark
obesity
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Reuters
Mon, 10/21/24 - 09:39 am
Novo Nordisk
Rybelsus
cardiovascular events
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
Pharma Voice
Mon, 10/21/24 - 09:37 am
FDA
GLP-1 agonists
Ozempic
Wegovy
Novo Nordisk
drug shortages
Eli Lilly
Zepbound
Chinese insulin maker says its GLP-1 beat Ozempic at lowering blood sugar, body weight in phase 2
Fierce Biotech
Wed, 10/16/24 - 12:17 pm
Gan & Lee
GLP-1
Novo Nordisk
Ozempic
type 2 diabetes
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
BioPharma Dive
Fri, 10/11/24 - 11:10 am
Novo Nordisk
Eli Lilly
obesity
Zebound
Wegovy
CagriSema
Amgen
MariTide
oforglipron
Veru
enobosarm
nimacimab
Skye Bioscience
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Reuters
Fri, 10/11/24 - 09:42 am
Novo Nordisk
artificial intelligence
India
R&D
Weight loss gold rush: Developers vie for next blockbuster treatment
Pharmaphorum
Tue, 10/8/24 - 09:45 am
R&D
obesity
weight loss
Novo Nordisk
Eli Lilly
Roche
Boehringer Ingelheim
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »